Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Genetic complexity in the replication-competent latent HIV reservoir increases with untreated infection duration in infected youth.

Brumme ZL, Sudderuddin H, Ziemniak C, Luzuriaga K, Jones BR, Joy JB, Cunningham CK, Greenough T, Persaud D.

AIDS. 2019 Feb 1;33(2):211-218. doi: 10.1097/QAD.0000000000002045.

PMID:
30325763
2.

Uveitis and Systemic Inflammatory Markers in Convalescent Phase of Ebola Virus Disease.

Chancellor JR, Padmanabhan SP, Greenough TC, Sacra R, Ellison RT 3rd, Madoff LC, Droms RJ, Hinkle DM, Asdourian GK, Finberg RW, Stroher U, Uyeki TM, Cerón OM.

Emerg Infect Dis. 2016 Feb;22(2):295-7. doi: 10.3201/eid2202.151416.

3.

A Gene Expression Signature That Correlates with CD8+ T Cell Expansion in Acute EBV Infection.

Greenough TC, Straubhaar JR, Kamga L, Weiss ER, Brody RM, McManus MM, Lambrecht LK, Somasundaran M, Luzuriaga KF.

J Immunol. 2015 Nov 1;195(9):4185-97. doi: 10.4049/jimmunol.1401513. Epub 2015 Sep 28.

4.

Epstein-Barr virus latent membrane protein 1 genetic variability in peripheral blood B cells and oropharyngeal fluids.

Renzette N, Somasundaran M, Brewster F, Coderre J, Weiss ER, McManus M, Greenough T, Tabak B, Garber M, Kowalik TF, Luzuriaga K.

J Virol. 2014 Apr;88(7):3744-55. doi: 10.1128/JVI.03378-13. Epub 2014 Jan 15.

5.

A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays.

Alpert MD, Heyer LN, Williams DE, Harvey JD, Greenough T, Allhorn M, Evans DT.

J Virol. 2012 Nov;86(22):12039-52. doi: 10.1128/JVI.01650-12. Epub 2012 Aug 29.

6.

Cross-reactivity and expansion of dengue-specific T cells during acute primary and secondary infections in humans.

Friberg H, Bashyam H, Toyosaki-Maeda T, Potts JA, Greenough T, Kalayanarooj S, Gibbons RV, Nisalak A, Srikiatkhachorn A, Green S, Stephens HA, Rothman AL, Mathew A.

Sci Rep. 2011;1:51. doi: 10.1038/srep00051. Epub 2011 Aug 1.

7.

Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir.

Persaud D, Luzuriaga K, Ziemniak C, Muresan P, Greenough T, Fenton T, Blackford A, Ferguson K, Neu N, Cunningham CK.

AIDS. 2011 Nov 28;25(18):2227-34. doi: 10.1097/QAD.0b013e32834cdaba.

8.

Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure.

Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson M.

PLoS Pathog. 2011 Feb;7(2):e1001303. doi: 10.1371/journal.ppat.1001303. Epub 2011 Feb 24.

9.

Programmed Death-1 expression on Epstein Barr virus specific CD8+ T cells varies by stage of infection, epitope specificity, and T-cell receptor usage.

Greenough TC, Campellone SC, Brody R, Jain S, Sanchez-Merino V, Somasundaran M, Luzuriaga K.

PLoS One. 2010 Sep 23;5(9):e12926. doi: 10.1371/journal.pone.0012926.

10.

Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy.

Shiu C, Cunningham CK, Greenough T, Muresan P, Sanchez-Merino V, Carey V, Jackson JB, Ziemniak C, Fox L, Belzer M, Ray SC, Luzuriaga K, Persaud D; Pediatric AIDS Clinical Trials Group P1059 Team.

J Virol. 2009 Oct;83(19):9731-42. doi: 10.1128/JVI.00570-09. Epub 2009 Jul 15.

11.

Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy.

Greenough TC, Cunningham CK, Muresan P, McManus M, Persaud D, Fenton T, Barker P, Gaur A, Panicali D, Sullivan JL, Luzuriaga K; Pediatric AIDS Clinical Trials Group P1059 Team.

Vaccine. 2008 Dec 9;26(52):6883-93. doi: 10.1016/j.vaccine.2008.09.084. Epub 2008 Oct 20.

12.

Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS.

Swingler S, Zhou J, Swingler C, Dauphin A, Greenough T, Jolicoeur P, Stevenson M.

Cell Host Microbe. 2008 Jul 17;4(1):63-76. doi: 10.1016/j.chom.2008.05.015.

13.

CD4 binding affinity determines human immunodeficiency virus type 1-induced alpha interferon production in plasmacytoid dendritic cells.

Haupt S, Donhauser N, Chaipan C, Schuster P, Puffer B, Daniels RS, Greenough TC, Kirchhoff F, Schmidt B.

J Virol. 2008 Sep;82(17):8900-5. doi: 10.1128/JVI.00196-08. Epub 2008 Jun 25.

14.

On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis.

Hadinoto V, Shapiro M, Greenough TC, Sullivan JL, Luzuriaga K, Thorley-Lawson DA.

Blood. 2008 Feb 1;111(3):1420-7. Epub 2007 Nov 8.

15.

Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.

Yuste E, Sanford HB, Carmody J, Bixby J, Little S, Zwick MB, Greenough T, Burton DR, Richman DD, Desrosiers RC, Johnson WE.

J Virol. 2006 Mar;80(6):3030-41.

16.

Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters.

Roberts A, Thomas WD, Guarner J, Lamirande EW, Babcock GJ, Greenough TC, Vogel L, Hayes N, Sullivan JL, Zaki S, Subbarao K, Ambrosino DM.

J Infect Dis. 2006 Mar 1;193(5):685-92. Epub 2006 Jan 27.

PMID:
16453264
17.

Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) infected with the severe acute respiratory syndrome-associated coronavirus.

Greenough TC, Carville A, Coderre J, Somasundaran M, Sullivan JL, Luzuriaga K, Mansfield K.

Am J Pathol. 2005 Aug;167(2):455-63.

18.

Nuclear localization of HIV type 1 Vif isolated from a long-term asymptomatic individual and potential role in virus attenuation.

Farrow MA, Somasundaran M, Zhang C, Gabuzda D, Sullivan JL, Greenough TC.

AIDS Res Hum Retroviruses. 2005 Jun;21(6):565-74. Erratum in: AIDS Res Hum Retroviruses. 2005 Aug;21(8):742.

PMID:
15989462
19.

Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins.

Tripp RA, Haynes LM, Moore D, Anderson B, Tamin A, Harcourt BH, Jones LP, Yilla M, Babcock GJ, Greenough T, Ambrosino DM, Alvarez R, Callaway J, Cavitt S, Kamrud K, Alterson H, Smith J, Harcourt JL, Miao C, Razdan R, Comer JA, Rollin PE, Ksiazek TG, Sanchez A, Rota PA, Bellini WJ, Anderson LJ.

J Virol Methods. 2005 Sep;128(1-2):21-8.

PMID:
15885812
20.

Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice.

Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD Jr, Coccia JA, Graziano RF, Srinivasan M, Lowy I, Finberg RW, Subbarao K, Vogel L, Somasundaran M, Luzuriaga K, Sullivan JL, Ambrosino DM.

J Infect Dis. 2005 Feb 15;191(4):507-14. Epub 2005 Jan 14.

PMID:
15655773
21.

Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2.

Li W, Greenough TC, Moore MJ, Vasilieva N, Somasundaran M, Sullivan JL, Farzan M, Choe H.

J Virol. 2004 Oct;78(20):11429-33.

22.

Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2.

Moore MJ, Dorfman T, Li W, Wong SK, Li Y, Kuhn JH, Coderre J, Vasilieva N, Han Z, Greenough TC, Farzan M, Choe H.

J Virol. 2004 Oct;78(19):10628-35.

23.

Alterations in HIV-1 LTR promoter activity during AIDS progression.

Hiebenthal-Millow K, Greenough TC, Bretttler DB, Schindler M, Wildum S, Sullivan JL, Kirchhoff F.

Virology. 2003 Dec 5;317(1):109-18.

24.

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.

Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M.

Nature. 2003 Nov 27;426(6965):450-4.

PMID:
14647384
25.
26.

Enhanced culture method for detection of replication-competent virus in peripheral blood mononuclear cells of HIV type 1-infected individuals.

Haran JP, Greenough TC, Luzuriaga K, Sullivan JL, Flanigan T, Somasundaran M.

AIDS Res Hum Retroviruses. 2002 May 20;18(8):577-83.

PMID:
12036487
27.
28.

Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS.

Carl S, Greenough TC, Krumbiegel M, Greenberg M, Skowronski J, Sullivan JL, Kirchhoff F.

J Virol. 2001 Apr;75(8):3657-65.

29.

Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection.

Alexander L, Weiskopf E, Greenough TC, Gaddis NC, Auerbach MR, Malim MH, O'Brien SJ, Walker BD, Sullivan JL, Desrosiers RC.

J Virol. 2000 May;74(9):4361-76.

30.

Resistance to apoptosis in HIV-infected CD4+ T lymphocytes is mediated by macrophages: role for Nef and immune activation in viral persistence.

Mahlknecht U, Deng C, Lu MC, Greenough TC, Sullivan JL, O'Brien WA, Herbein G.

J Immunol. 2000 Dec 1;165(11):6437-46.

31.

Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy.

Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, Bucy RP, Kostrikis LG, Haase A, Veryard C, Davaro RE, Cheeseman SH, Daly JS, Bova C, Ellison RT 3rd, Mady B, Lai KK, Moyle G, Nelson M, Gazzard B, Shaunak S, Stevenson M.

Nat Med. 2000 Jan;6(1):76-81.

PMID:
10613828
32.

Partial "repair" of defective NEF genes in a long-term nonprogressor with human immunodeficiency virus type 1 infection.

Carl S, Daniels R, Iafrate AJ, Easterbrook P, Greenough TC, Skowronski J, Kirchhoff F.

J Infect Dis. 2000 Jan;181(1):132-40.

PMID:
10608759
33.

Long-term nonprogressive infection with human immunodeficiency virus type 1 in a hemophilia cohort.

Greenough TC, Brettler DB, Kirchhoff F, Alexander L, Desrosiers RC, O'Brien SJ, Somasundaran M, Luzuriaga K, Sullivan JL.

J Infect Dis. 1999 Dec;180(6):1790-802.

PMID:
10558933
34.

Sequence variations in human immunodeficiency virus type 1 Nef are associated with different stages of disease.

Kirchhoff F, Easterbrook PJ, Douglas N, Troop M, Greenough TC, Weber J, Carl S, Sullivan JL, Daniels RS.

J Virol. 1999 Jul;73(7):5497-508.

35.

Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1.

Greenough TC, Sullivan JL, Desrosiers RC.

N Engl J Med. 1999 Jan 21;340(3):236-7. No abstract available.

PMID:
9917232
36.

Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: a case series.

Rich JD, Merriman NA, Mylonakis E, Greenough TC, Flanigan TP, Mady BJ, Carpenter CC.

Ann Intern Med. 1999 Jan 5;130(1):37-9.

PMID:
9890848
38.

Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.

Means RE, Greenough T, Desrosiers RC.

J Virol. 1997 Oct;71(10):7895-902.

39.

Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo.

Greenough TC, Brettler DB, Somasundaran M, Panicali DL, Sullivan JL.

J Infect Dis. 1997 Jul;176(1):118-25.

PMID:
9207357
40.
41.

High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection.

Mariani R, Kirchhoff F, Greenough TC, Sullivan JL, Desrosiers RC, Skowronski J.

J Virol. 1996 Nov;70(11):7752-64.

42.

Bartonella henselae endocarditis in an immunocompetent adult.

Holmes AH, Greenough TC, Balady GJ, Regnery RL, Anderson BE, O'Keane JC, Fonger JD, McCrone EL.

Clin Infect Dis. 1995 Oct;21(4):1004-7.

PMID:
8645787
43.

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection.

Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D, Myers M, et al.

J Infect Dis. 1995 Mar;171(3):537-45.

PMID:
7533197
44.

Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.

Cheeseman SH, Havlir D, McLaughlin MM, Greenough TC, Sullivan JL, Hall D, Hattox SE, Spector SA, Stein DS, Myers M, et al.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Feb 1;8(2):141-51.

PMID:
7530585
45.

Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.

Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC.

N Engl J Med. 1995 Jan 26;332(4):228-32. No abstract available.

46.

Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection.

Greenough TC, Somasundaran M, Brettler DB, Hesselton RM, Alimenti A, Kirchhoff F, Panicali D, Sullivan JL.

AIDS Res Hum Retroviruses. 1994 Apr;10(4):395-403.

PMID:
8068417
47.

Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas.

Ayash LJ, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, Elias A, Antin JH, Greenough T, Eder JP.

J Clin Oncol. 1990 Oct;8(10):1699-706.

PMID:
2213105
48.

Remodeling of sperm chromatin following fertilization: nucleosome repeat length and histone variant transitions in the absence of DNA synthesis.

Poccia D, Greenough T, Green GR, Nash E, Erickson J, Gibbs M.

Dev Biol. 1984 Aug;104(2):274-86.

PMID:
6430734
49.

Suppression of operant responding with overt and covert aversive stimuli of high and low intensity.

Greenough TJ.

Psychol Rep. 1978 Dec;43(3 Pt 1):831-7. No abstract available.

PMID:
740826
50.

Psychological and social adjustment of blind subjects and the 16PF.

Greenough TJ, Keegan DL, Ash DG.

J Clin Psychol. 1978 Jan;34(1):84-7.

PMID:
641190

Supplemental Content

Loading ...
Support Center